Journal: Cancers

Article Title: ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors

doi: 10.3390/cancers14235951

Figure Lengend Snippet: TIDE biomarker evaluation of ACAP1 in response to immunotherapy across diverse cancers.

Article Snippet: The primary antibodies: ACAP1 (ProteinTech, #66596-1-Ig), SPI1 (ProteinTech, #66618-2-Ig), HIF1α (ProteinTech, #20960-1-AP), and GAPDH (ProteinTech, #60004-1-Ig).

Techniques: Biomarker Discovery

Journal: Cancers

Article Title: ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors

doi: 10.3390/cancers14235951

Figure Lengend Snippet: ACAP1 mRNA expression across different tissues and cell lines. ( A ) Violin plots of ACAP1 expression levels across all available tissues ordered by ACAP1 expression in the GTEx Portal. ( B ) ACAP1 expression levels in human tissues and cell lines were visualized by BioGPS. Red: tissues and cells with relatively high ACAP1 expression. ( C ) Violin plots of ACAP1 expression levels across different types of cancer cell lines in the CCLE dataset. ( D ) The protein levels of ACAP1 from indicated cell lines were determined by Western blotting.

Article Snippet: The primary antibodies: ACAP1 (ProteinTech, #66596-1-Ig), SPI1 (ProteinTech, #66618-2-Ig), HIF1α (ProteinTech, #20960-1-AP), and GAPDH (ProteinTech, #60004-1-Ig).

Techniques: Expressing, Western Blot

Journal: Cancers

Article Title: ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors

doi: 10.3390/cancers14235951

Figure Lengend Snippet: Single-cell gene expression analysis of ACAP1. ( A , B ) Single-cell RNA sequencing analyses of ACAP1 mRNA expression across various cell types in melanoma datasets GSE72096 and GSE115978. ( C ) Single-cell expression patterns of ACAP1 in the glioblastoma dataset “Neftel 2019” are shown with tSNE plots. ( D , E ) Single-cell expression patterns of ACAP1 in prostate cancer datasets, including “He 2021” and “Wu 2021 (PC-P1)”, are shown with UMAP plots. ( F ) Single-cell expression patterns of ACAP1 in the cutaneous melanoma dataset “Wu 2021 (M-P1)” are shown with UMAP plots. ( G – I ) Single-cell expression patterns of ACAP1 in breast cancer datasets, including “Wu 2021 (BC-P1)”, “Wu 2021 (BC-P2)”, and “Wu 2021 (BC-P3)”, are shown with UMAP plots.

Article Snippet: The primary antibodies: ACAP1 (ProteinTech, #66596-1-Ig), SPI1 (ProteinTech, #66618-2-Ig), HIF1α (ProteinTech, #20960-1-AP), and GAPDH (ProteinTech, #60004-1-Ig).

Techniques: Gene Expression, RNA Sequencing, Expressing

Journal: Cancers

Article Title: ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors

doi: 10.3390/cancers14235951

Figure Lengend Snippet: Pan-cancer analysis of ACAP1 expression in human cancer. ( A ) Comparing of ACAP1 mRNA levels in tumor vs. normal samples across TCGA cancer types by combing the TCGA and GTEx data. ( B ) Paired comparison of ACAP1 mRNA levels in tumor vs. normal samples in TCGA. Green: decreased ACAP1 expression in tumors; Red: elevated gene expression in tumors. ( C ) Comparison of ACAP1 protein levels in tumor vs. normal samples across all cancer types available in CPTAC using UALCAN webtool. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, ns (non-significant).

Article Snippet: The primary antibodies: ACAP1 (ProteinTech, #66596-1-Ig), SPI1 (ProteinTech, #66618-2-Ig), HIF1α (ProteinTech, #20960-1-AP), and GAPDH (ProteinTech, #60004-1-Ig).

Techniques: Expressing, Comparison, Gene Expression

Journal: Cancers

Article Title: ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors

doi: 10.3390/cancers14235951

Figure Lengend Snippet: Implications of ACAP1 expression on overall survival of cancer patients across multiple cancer types. ( A – U ) Overall survival analyses of cancer patients stratified by ACAP1 mRNA level with the Kaplan–Meier method in TCGA datasets. ( V – Y ) Overall survival analyses of cancer patients stratified by ACAP1 mRNA level in ICGC-LIRI-JP(LIHC), GSE68465(LUAD), GSE22153(SKCM), and CGGA325(GBM) datasets.

Article Snippet: The primary antibodies: ACAP1 (ProteinTech, #66596-1-Ig), SPI1 (ProteinTech, #66618-2-Ig), HIF1α (ProteinTech, #20960-1-AP), and GAPDH (ProteinTech, #60004-1-Ig).

Techniques: Expressing

Journal: Cancers

Article Title: ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors

doi: 10.3390/cancers14235951

Figure Lengend Snippet: Transcriptional regulation of ACAP1. ( A ) Heatmap of TCGA samples (I), ACAP1 mRNA expression (II), β-value (methylation level) of 4 CpG sites, including cg13295242, cg13670306, cg11807006, and cg25671438, in the ACAP1 promoter region (III), copy number variation (IV), and SPI1 mRNA expression (V) in TCGA pan-cancer dataset. The samples were ordered by ACAP1 expression. Blue: low level; Red: high level. ( B ) Violin plots showing the β-value of cg25671438 in indicated cancers of TCGA. ( C , D ) Violin plots showing the β-value of cg25671438 and the average β-value of 4 CpG sites in indicated cancer cell lines of GSE68379. ( E ) Heatmap of the Spearman correlation coefficient of ACAP1 mRNA levels with β value of CpG sites in ACAP1 promoter and copy number across 33 cancer types in TCGA. ( F ) The β-value of 4 CpG sites in the ACAP1 promoter region of Huh-7 and SK-HEP-1 cells in GSE68379. ( G ) The impact of 5-aza on ACAP1 mRNA level in Huh-7 and SK-HEP-1 cells. ** p < 0.01, * p < 0.05.

Article Snippet: The primary antibodies: ACAP1 (ProteinTech, #66596-1-Ig), SPI1 (ProteinTech, #66618-2-Ig), HIF1α (ProteinTech, #20960-1-AP), and GAPDH (ProteinTech, #60004-1-Ig).

Techniques: Expressing, Methylation

Journal: Cancers

Article Title: ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors

doi: 10.3390/cancers14235951

Figure Lengend Snippet: Transcriptional regulation of ACAP1 by SPI1. ( A ) Heatmap of the correlation coefficient of ACAP1 mRNA levels and SPI1 levels across 33 cancer types in TCGA. ( B ) Scatter plot displays the SPI1 and ACAP1 mRNA expression in EBV-transformed lymphocytes of GTEx dataset. ( C ) Scatter plot displays the SPI1 and ACAP1 mRNA expression in whole blood of GTEx dataset. ( D ) ChIP-sequencing peaks of SPI1 in macrophage, B lymphocyte, and lymphoma; H3K4me3 in Ramos B-lymphocytes, Jurkat T-cell, A549 lung cancer cells, Capan-1 pancreatic ductal cancer cells, Hela-S3 cervix cancer cells, HCT116 colon cancer cells, DU145 prostate cancer cells, esophagus cells, brain cells, and MDA-MB-231 breast cancer cells. The binding region of SPI1 on ACAP1 promoter is highlighted in cyan shaded box. The SPI1 binding sites on ACAP1 promoter predicted by JASPAR are shown. ( E ) SPI1 binding motif MA0080.1 and MA0080.2 from JASPAR curated motif database. ( F ) ChIP-PCR showed SPI1 binds to the promoter of ACAP1 in Jurkat cells. ( G ) Analysis of SPI1 overexpression on ACAP1 protein expression in Jurkat by Western blotting. ( H ) Effects of hypoxia-mimicking CoCl 2 treatment on HIF1α, SPI1, and ACAP1 expression in Jurkat cells were determined by Western blotting, ** p < 0.01, * p < 0.05.

Article Snippet: The primary antibodies: ACAP1 (ProteinTech, #66596-1-Ig), SPI1 (ProteinTech, #66618-2-Ig), HIF1α (ProteinTech, #20960-1-AP), and GAPDH (ProteinTech, #60004-1-Ig).

Techniques: Expressing, Transformation Assay, ChIP-sequencing, Binding Assay, Over Expression, Western Blot

Journal: Cancers

Article Title: ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors

doi: 10.3390/cancers14235951

Figure Lengend Snippet: The Spearman correlations of ACAP1 expression with immune cell infiltration across 32 cancer types in TCGA.

Article Snippet: The primary antibodies: ACAP1 (ProteinTech, #66596-1-Ig), SPI1 (ProteinTech, #66618-2-Ig), HIF1α (ProteinTech, #20960-1-AP), and GAPDH (ProteinTech, #60004-1-Ig).

Techniques: Expressing

Journal: Cancers

Article Title: ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors

doi: 10.3390/cancers14235951

Figure Lengend Snippet: ACAP1 knockdown impairs the cytotoxicity of T cells against tumor cells. ( A ) Western blotting of lysates from TALL-104 cells infected with control or two different ACAP1-targeting shRNA lentiviruses. ( B ) Representative images of live/dead A549 cells co-cultured with different TALL-104 cells at a 1:2 cell ratio for 24 h were shown. Red-fluorescent PI (propidium iodide) was used to detect dead cells. Green-fluorescent CMFDA (5-chloromethylfluorescein diacetate) was used to detect live cells. Scale bars, 100 μm. ( C ) Three random fields were analyzed, and live/dead cell ratios were quantified. * p < 0.05.

Article Snippet: The primary antibodies: ACAP1 (ProteinTech, #66596-1-Ig), SPI1 (ProteinTech, #66618-2-Ig), HIF1α (ProteinTech, #20960-1-AP), and GAPDH (ProteinTech, #60004-1-Ig).

Techniques: Knockdown, Western Blot, Infection, Control, shRNA, Cell Culture

Journal: Cancers

Article Title: ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors

doi: 10.3390/cancers14235951

Figure Lengend Snippet: ACAP1 deficiency correlates with inferior ICT response and prognosis in multiple cancer types. ( A ) ACAP1 expression in different response groups; Kaplan–Meier OS and PFS estimates according to ACAP1 expression in “VanAllen2015” cohort, of which melanoma patients were treated with anti-CTLA-4 antibody (ipilimumab). ( B ) ACAP1 expression in different response groups; Kaplan–Meier OS estimates according to ACAP1 expression in “Snyder 2014” cohort, in which melanoma patients were treated with anti-CTLA-4 antibody (tremelimumab or ipilimumab). ( C ) ACAP1 expression in different response groups; Kaplan–Meier OS and PFS estimates according to ACAP1 expression in the “Gide 2019” cohort, in which melanoma patients were treated with anti-PD1 antibody (nivolumab or pembrolizumab) or anti-CTLA-4/PD-1 antibody (ipilimumab + pembrolizumab) (one patient with the extreme value of ACAP1 expression was excluded). ( D ) ACAP1 expression in different response groups; Kaplan–Meier OS estimates according to ACAP1 expression in both “prior to therapy” and “during therapy” groups of “Riaz 2017” cohort, in which melanoma patients were treated with anti-PD1 antibody (nivolumab). ( E ) Kaplan–Meier OS and PFS estimate according to ACAP1 expression in the “Miao 2018” cohort, in which RCC patients were treated with anti-PD-1 and/or anti-CTLA-4 antibodies (nivolumab or atezolizumab or nivolumab + ipilimumab). ( F ) ACAP1 expression in different response groups in the “Ruppin 2021” cohort, of which LUAD (lung adenocarcinoma) patients were treated with anti-PD-1 antibody (pembrolizumab). ( G ) ACAP1 expression in different response groups; Kaplan–Meier OS and PFS estimates according to ACAP1 expression in GSE126044, in which NSCLC patients were treated with anti-PD-1 antibody (nivolumab). ( H ) ACAP1 expression in different response groups; Kaplan–Meier OS estimates according to ACAP1 expression in the “IMvigor210” cohort, in which mUC patients were treated with anti-PD-L1 antibody (atezolizumab). OS: overall survival. PFS: progression-free survival. Kaplan–Meier survival curves with p -values derived by log-rank test were shown. *** p < 0.001, ** p < 0.01, * p < 0.05.

Article Snippet: The primary antibodies: ACAP1 (ProteinTech, #66596-1-Ig), SPI1 (ProteinTech, #66618-2-Ig), HIF1α (ProteinTech, #20960-1-AP), and GAPDH (ProteinTech, #60004-1-Ig).

Techniques: Expressing, Derivative Assay